ADAR1: A New Target for Immuno-oncology Therapy

Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cell 2019-03, Vol.73 (5), p.866-868
Hauptverfasser:	Bhate, Amruta, Sun, Tao, Li, Jin Billy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Deaminase - genetics Adenosine Deaminase - immunology Adenosine Deaminase - metabolism Animals Cell Survival CRISPR-Cas Systems Gene Editing Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic Genetic Therapy - methods Humans Immunity, Innate Immunotherapy - methods Interferon-Induced Helicase, IFIH1 - genetics Interferon-Induced Helicase, IFIH1 - metabolism Neoplasms - enzymology Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy RNA Editing RNA, Double-Stranded - genetics RNA, Double-Stranded - immunology RNA, Double-Stranded - metabolism RNA-Binding Proteins - genetics RNA-Binding Proteins - immunology RNA-Binding Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	868
container_issue	5
container_start_page	866
container_title	Molecular cell
container_volume	73
creator	Bhate, Amruta Sun, Tao Li, Jin Billy
description	Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
doi_str_mv	10.1016/j.molcel.2019.02.021
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2189546462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1097276519301327</els_id><sourcerecordid>2189546462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-8ab8353aebe0ca5a6eaf15b470caa7e7c362ee4273fef45aff7b1bd730b7834e3</originalsourceid><addsrcrecordid>eNp9UE1Lw0AUXESxtfoPRHL0krhfySYehFC_CkVB6nnZbF5qSpKtu4nSf--WVI_CwHsPZt4wg9AlwRHBJLnZRK1pNDQRxSSLMPUgR2hKcCZCThJ-fNipSOIJOnNugzHhcZqdognDKc9YxqboJr_P38htkAcv8B2slF1DH1TGBou2HToTmk6bxqx3weoDrNruztFJpRoHF4c5Q--PD6v5c7h8fVrM82WoOU77MFVFymKmoACsVawSUBWJCy78pQQIzRIKwKlgFVQ8VlUlClKUguFCpIwDm6Hr8e_Wms8BXC_b2vm0jerADE5SkmYxT3hCPZWPVG2NcxYqubV1q-xOEiz3VcmNHKuS-6okph7Ey64ODkPRQvkn-u3GE-5GAvicXzVY6XQNnYaytqB7WZr6f4cf4yJ6rA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2189546462</pqid></control><display><type>article</type><title>ADAR1: A New Target for Immuno-oncology Therapy</title><source>MEDLINE</source><source>Cell Press Free Archives</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Bhate, Amruta ; Sun, Tao ; Li, Jin Billy</creator><creatorcontrib>Bhate, Amruta ; Sun, Tao ; Li, Jin Billy</creatorcontrib><description>Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.</description><identifier>ISSN: 1097-2765</identifier><identifier>EISSN: 1097-4164</identifier><identifier>DOI: 10.1016/j.molcel.2019.02.021</identifier><identifier>PMID: 30849393</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenosine Deaminase - genetics ; Adenosine Deaminase - immunology ; Adenosine Deaminase - metabolism ; Animals ; Cell Survival ; CRISPR-Cas Systems ; Gene Editing ; Gene Expression Regulation, Enzymologic ; Gene Expression Regulation, Neoplastic ; Genetic Therapy - methods ; Humans ; Immunity, Innate ; Immunotherapy - methods ; Interferon-Induced Helicase, IFIH1 - genetics ; Interferon-Induced Helicase, IFIH1 - metabolism ; Neoplasms - enzymology ; Neoplasms - genetics ; Neoplasms - immunology ; Neoplasms - therapy ; RNA Editing ; RNA, Double-Stranded - genetics ; RNA, Double-Stranded - immunology ; RNA, Double-Stranded - metabolism ; RNA-Binding Proteins - genetics ; RNA-Binding Proteins - immunology ; RNA-Binding Proteins - metabolism</subject><ispartof>Molecular cell, 2019-03, Vol.73 (5), p.866-868</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-8ab8353aebe0ca5a6eaf15b470caa7e7c362ee4273fef45aff7b1bd730b7834e3</citedby><cites>FETCH-LOGICAL-c408t-8ab8353aebe0ca5a6eaf15b470caa7e7c362ee4273fef45aff7b1bd730b7834e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.molcel.2019.02.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30849393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhate, Amruta</creatorcontrib><creatorcontrib>Sun, Tao</creatorcontrib><creatorcontrib>Li, Jin Billy</creatorcontrib><title>ADAR1: A New Target for Immuno-oncology Therapy</title><title>Molecular cell</title><addtitle>Mol Cell</addtitle><description>Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.</description><subject>Adenosine Deaminase - genetics</subject><subject>Adenosine Deaminase - immunology</subject><subject>Adenosine Deaminase - metabolism</subject><subject>Animals</subject><subject>Cell Survival</subject><subject>CRISPR-Cas Systems</subject><subject>Gene Editing</subject><subject>Gene Expression Regulation, Enzymologic</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic Therapy - methods</subject><subject>Humans</subject><subject>Immunity, Innate</subject><subject>Immunotherapy - methods</subject><subject>Interferon-Induced Helicase, IFIH1 - genetics</subject><subject>Interferon-Induced Helicase, IFIH1 - metabolism</subject><subject>Neoplasms - enzymology</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>RNA Editing</subject><subject>RNA, Double-Stranded - genetics</subject><subject>RNA, Double-Stranded - immunology</subject><subject>RNA, Double-Stranded - metabolism</subject><subject>RNA-Binding Proteins - genetics</subject><subject>RNA-Binding Proteins - immunology</subject><subject>RNA-Binding Proteins - metabolism</subject><issn>1097-2765</issn><issn>1097-4164</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UE1Lw0AUXESxtfoPRHL0krhfySYehFC_CkVB6nnZbF5qSpKtu4nSf--WVI_CwHsPZt4wg9AlwRHBJLnZRK1pNDQRxSSLMPUgR2hKcCZCThJ-fNipSOIJOnNugzHhcZqdognDKc9YxqboJr_P38htkAcv8B2slF1DH1TGBou2HToTmk6bxqx3weoDrNruztFJpRoHF4c5Q--PD6v5c7h8fVrM82WoOU77MFVFymKmoACsVawSUBWJCy78pQQIzRIKwKlgFVQ8VlUlClKUguFCpIwDm6Hr8e_Wms8BXC_b2vm0jerADE5SkmYxT3hCPZWPVG2NcxYqubV1q-xOEiz3VcmNHKuS-6okph7Ey64ODkPRQvkn-u3GE-5GAvicXzVY6XQNnYaytqB7WZr6f4cf4yJ6rA</recordid><startdate>20190307</startdate><enddate>20190307</enddate><creator>Bhate, Amruta</creator><creator>Sun, Tao</creator><creator>Li, Jin Billy</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190307</creationdate><title>ADAR1: A New Target for Immuno-oncology Therapy</title><author>Bhate, Amruta ; Sun, Tao ; Li, Jin Billy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-8ab8353aebe0ca5a6eaf15b470caa7e7c362ee4273fef45aff7b1bd730b7834e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adenosine Deaminase - genetics</topic><topic>Adenosine Deaminase - immunology</topic><topic>Adenosine Deaminase - metabolism</topic><topic>Animals</topic><topic>Cell Survival</topic><topic>CRISPR-Cas Systems</topic><topic>Gene Editing</topic><topic>Gene Expression Regulation, Enzymologic</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic Therapy - methods</topic><topic>Humans</topic><topic>Immunity, Innate</topic><topic>Immunotherapy - methods</topic><topic>Interferon-Induced Helicase, IFIH1 - genetics</topic><topic>Interferon-Induced Helicase, IFIH1 - metabolism</topic><topic>Neoplasms - enzymology</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>RNA Editing</topic><topic>RNA, Double-Stranded - genetics</topic><topic>RNA, Double-Stranded - immunology</topic><topic>RNA, Double-Stranded - metabolism</topic><topic>RNA-Binding Proteins - genetics</topic><topic>RNA-Binding Proteins - immunology</topic><topic>RNA-Binding Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhate, Amruta</creatorcontrib><creatorcontrib>Sun, Tao</creatorcontrib><creatorcontrib>Li, Jin Billy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular cell</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhate, Amruta</au><au>Sun, Tao</au><au>Li, Jin Billy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ADAR1: A New Target for Immuno-oncology Therapy</atitle><jtitle>Molecular cell</jtitle><addtitle>Mol Cell</addtitle><date>2019-03-07</date><risdate>2019</risdate><volume>73</volume><issue>5</issue><spage>866</spage><epage>868</epage><pages>866-868</pages><issn>1097-2765</issn><eissn>1097-4164</eissn><abstract>Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30849393</pmid><doi>10.1016/j.molcel.2019.02.021</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1097-2765
ispartof	Molecular cell, 2019-03, Vol.73 (5), p.866-868
issn	1097-2765 1097-4164
language	eng
recordid	cdi_proquest_miscellaneous_2189546462
source	MEDLINE; Cell Press Free Archives; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry
subjects	Adenosine Deaminase - genetics Adenosine Deaminase - immunology Adenosine Deaminase - metabolism Animals Cell Survival CRISPR-Cas Systems Gene Editing Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic Genetic Therapy - methods Humans Immunity, Innate Immunotherapy - methods Interferon-Induced Helicase, IFIH1 - genetics Interferon-Induced Helicase, IFIH1 - metabolism Neoplasms - enzymology Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy RNA Editing RNA, Double-Stranded - genetics RNA, Double-Stranded - immunology RNA, Double-Stranded - metabolism RNA-Binding Proteins - genetics RNA-Binding Proteins - immunology RNA-Binding Proteins - metabolism
title	ADAR1: A New Target for Immuno-oncology Therapy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T21%3A48%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ADAR1:%20A%20New%20Target%20for%20Immuno-oncology%20Therapy&rft.jtitle=Molecular%20cell&rft.au=Bhate,%20Amruta&rft.date=2019-03-07&rft.volume=73&rft.issue=5&rft.spage=866&rft.epage=868&rft.pages=866-868&rft.issn=1097-2765&rft.eissn=1097-4164&rft_id=info:doi/10.1016/j.molcel.2019.02.021&rft_dat=%3Cproquest_cross%3E2189546462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2189546462&rft_id=info:pmid/30849393&rft_els_id=S1097276519301327&rfr_iscdi=true